Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 11/20 | 0.73 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.50 |
| ▸ | PHLPP1 | O60346 | 3/20 | 0.50 |
| ▸ | ILK | Q13418 | 3/20 | 0.50 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.39 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5839319 | 1.00 | AKT1 (0.73) | AKT1PDPK1PHLPP1ILKBCHE | |
| SCHEMBL4259671 | 0.81 | AKT1 (0.91) | AKT1PDPK1PHLPP1ILKLMNA | |
| SCHEMBL14544421 | 0.79 | PSEN1 (0.50) | AKT1LMNANR1I2ALOX5PSEN1 | |
| SCHEMBL5839569 | 0.76 | AKT1 (0.59) | AKT1PDPK1PHLPP1ILK | |
| SCHEMBL16518643 | 0.75 | PPARA (0.55) | AKT1PDPK1PHLPP1ILKLMNA | |
| SCHEMBL5838691 | 0.75 | MEN1 (0.45) | AKT1LMNANR1I2PSEN1 | |
| SCHEMBL12064998 | 0.74 | PSEN1 (0.66) | AKT1LMNANR1I2PSEN1 | |
| SCHEMBL16077012 | 0.74 | ALOX5 (0.63) | AKT1NR1I2ALOX5 | |
| SCHEMBL13084640 | 0.72 | PSEN1 (0.55) | AKT1LMNANR1I2ALOX5PSEN1 | |
| SCHEMBL5839697 | 0.72 | PSEN1 (0.44) | AKT1LMNANR1I2ALOX5PSEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115657-B2 | Bifunctional agents possessing antioxidant and antiarrhythmic activity | UNI-PHARMA KLEON TSETIS PHARMACEUTICAL LABORATORIES S.A. (GR) | 2006-10-03 | — | — | US | disclosed |
| US-20040259763-A1 | Bifunctional agents possessing antioxidant and antiarrhythmic activity | UNI-PHARMA KLEON TSETIS PHARMACEUTICAL LABORATORIES S.A. (GR) | 2004-12-23 | — | — | US | disclosed |
| EP-1301504-B1 | BIFUNCTIONAL AGENTS POSSESSING ANTIOXIDANT AND ANTIARRHYTHMIC ACTIVITY | UNI PHARMA KLEON TSETIS PHARMACEUTICAL LAB SA (GR) | 2004-11-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259763-A1 | Bifunctional agents possessing antioxidant and antiarrhythmic activity | GPX4, GSR, GPX1 | AKT1 1135/4885PDPK1 1705/4885PHLPP1 3742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.